A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

  • days left to enroll
  • participants needed
  • sponsor
    Everfront Biotech Co., Ltd.
Updated on 4 October 2022


A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profile of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma.

High grade gliomas, glioblastoma multiforme (grade IV) and anaplastic anaplastic astrocytoma (Grade III), are the most comment malignant brain tumor. The cause of gliomas remains unknown. Despite of several researches on environmental hazards and genetic alterations, no direct causes were found.

Patient suffering from glioma usually develops symptoms such as headaches, seizures, memory loss and changes in behavior in its early phase. At later stages, patients may encounter loss of movement and sensation, language dysfunction and cognitive impairments depending on location and size of the tumor. The average survival of glioblastoma patients is 15 months regardless of the use of multimodal therapy.

(Z)-BP/polymer wafer, designated as Cerebraca wafer, is a biodegradable wafer for interstitial implantation comprises (Z)-n-butylidenephthalide ((Z)-BP; the active moiety) and Carboxyphenoxypropane-Sebacic Acid Copolymer (CPPSA; the excipient).

Cerebraca wafer, the first human-use drug product, is a biodegradable implant comprises (Z)-n-butylidenephthalide ((Z)-BP) and CPPSA. According to pre-clinical study, (Z)-BP could reduce glioma migration and invasion, it also could reduce the tumor stem cell marker gens.


There are a main study period and extended period in this study. Main study period Screening Day -30~-1

  1. informed consent signed/given
  2. Screening evaluation Day 0~7

(1) Tumor resection and Cerebraca wafer implantation (2)Blood sampling for PK (3) Blood sampling for PD (4) Evaluation Day10~24

  1. Blood sampling for PK
  2. Blood sampling for PD
  3. Evaluation Extended period/Follow-up:Every 56 days (8 weeks) The main study will end at 24 weeks after all patients (including Phase I and IIa) receive Cerebraca implantation. If confirmation tumor response assessment is needed, additional 4 weeks study duration for Main Study Period is allowed.

All patients will be followed in the Extended Period for the efficacy and safety profiles until any one of study cut-off criteria is met.

Study cut-off criteria: (Applies to phase I and IIa) (1)90% patient died or loss of follow-up (2)2 years after the last patient receives Cerebraca wafer implantation

Condition Recurrent Malignant Glioma, Recurrent High Grade Glioma
Treatment Cerebraca wafer
Clinical Study IdentifierNCT03234595
SponsorEverfront Biotech Co., Ltd.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Female or male, age 20 years old
Patient has diagnosed recurrent high grade glioma, including anaplastic astrocytoma and glioblastoma multiforme
Patients have enough cavity after glioma resection for planned number of wafer implantation (by Investigator's judgment)
Patients have unilateral single focus of tumor in cerebrum
Patients have the 1st time recurrence of glioma
Patients undergone standard therapy for their prior glioma episode; for patients with anaplastic astrocytoma, the prior standard therapy should include surgical resection, radiation and adjuvant temozolomide (or PCV [procarzine, lomustine and vincristine]; for patients with glioblastoma multiforme the prior standard therapy should include surgical resection, radiation and adjuvant temozolomide
Patients with Karnofsky Performance Score (KPS) 50
Patients are recovered from toxicities from prior systemic therapies and have adequate hematopoietic function at screening and before using study medication
Absolute neutrophil count (ANC) 1,000 cells /mm3
Platelets 100,000 /mm3
Total white blood cell (WBC) 2,500 cells /mm3
Total bilirubin 2.5 mg/dL
Creatinine 2.0 mg/dL
GFR 30 ml/min/1.73m2
Patient with no or mild organ impairment
Patients who are eligible and able to participate in the study and accept to enter the study by signing written informed consent forms
Patients agrees not to use food supplementary or dietary that contains Angelica sinensis after Screening Visit to Day 21
All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) for at least 4 weeks after Cerebraca wafer treatment and TMZ treatment (whichever is longer) shown below
Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception)
Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
Combination of any two of the following (a+b or a+c, or b+c)
Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
Placement of an intrauterine device (IUD) or intrauterine system (IUS)
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
Phase IIa The inclusion criteria for Phase IIa is the same as in Phase I

Exclusion Criteria

Phase I and IIa
Patient who has participated in other investigational studies within 4 weeks prior to receive Cerebraca wafer
Patient with known or suspected hypersensitivity to Cerebraca wafer, TMZ or the excipient
Patient has tumor that cannot be surgically removed without significantly affecting vital function
Patient's glioma locates in the area that is not suitable for Cerebraca wafer implantation
Patient has external-beam radiation therapy within 4 weeks before study entry
Patient has other severe and/or life-threatening disease(s) with life expectancy less than 12 months
Patient has immuno-compromised condition, or is with known autoimmune conditions or is human immunodeficiency virus (HIV) seropositive
Patient with medical, social or psychological factors interfering with compliance of the study
Patient has on-going moderate to severe organ impairment other than study indication that may confound the efficacy evaluation, safety evaluation or usage of TMZ
At Phase I, patient is planning to use strong cytochrome P450 modulator
Female patients are lactating, pregnant, or planned to be pregnant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note